Addex Therapeutics Ltd - ADR Stock

$7.52

3.71% day before yesterday

Nasdaq, Dec 27, 10:00 pm CET

ISIN

US00654J1079

Symbol

ADXN

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Addex Therapeutics Ltd - ADR Stock price

$7.52

-282.48 97.41% 5Y

Nasdaq, Closing price Fri, Dec 27 2024

-0.29 3.71%

ISIN

US00654J1079

Symbol

ADXN

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$6.16m
Enterprise Value	$2.24m
P/E (TTM) P/E ratio	1.10
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	3.34
P/S ratio (TTM) P/S ratio	9.19
P/B ratio (TTM) P/B ratio	0.47
Revenue growth (TTM) Revenue growth	-70.05%
Revenue (TTM) Revenue	$670.00k
EBIT (operating result TTM) EBIT	$-5.64m
Free Cash Flow (TTM) Free Cash Flow	$-6.59m
Cash position	$3.97m
EPS (TTM) EPS	$6.82
P/S forward	10.50
EV/Sales forward	3.82
Short interest	0.41%

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Get Started for Free Today

Addex Therapeutics Ltd - ADR Stock Analysis

Unlock Scores for Free

??

2 Analysts have issued a Addex Therapeutics Ltd - ADR forecast:

1x Buy

50%

1x Sell

50%

More details on Analyst Estimates Including Price Targets

2 Analysts have issued a Addex Therapeutics Ltd - ADR forecast:

Buy

50%

Sell

50%

Analyst Estimates with Stock Price Targets

Financial data from Addex Therapeutics Ltd - ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Sep '24		+/- %
Revenue	0.67 0.67	70% 70% 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	3.17 3.17	41% 41% 473%
- Research and Development Expense	2.58 2.58	69% 69% 385%
EBITDA	-5.36 -5.36	54% 54% -800%
- Depreciation and Amortization	0.28 0.28	15% 15% 42%
EBIT (Operating Income) EBIT	-5.64 -5.64	53% 53% -841%
Net Profit	5.72 5.72	146% 146% 854%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Addex Therapeutics Ltd - ADR Stock News

Neutral

Seeking Alpha

●

about one month ago

Addex Therapeutics Ltd (ADXN) Q3 2024 Earnings Call Transcript

Addex Therapeutics Ltd (NASDAQ:ADXN ) Q3 2024 Earnings Conference Call November 22, 2024 10:00 AM ET Company Participants Tim Dyer - Co-Founder, Board Director and Chief Executive Officer Mikhail Kalinichev - Head, Translational Science Conference Call Participants Operator Good day, and thank you for standing by. Welcome to the Addex Therapeutics Third Quarter 2024 Financial Results and Corpor...

Neutral

GlobeNewsWire

●

about one month ago

Addex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Indivior selected GABA B PAM drug candidate for development in substance use disorders (SUD) and starts IND enabling studies Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 22, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders...

Neutral

GlobeNewsWire

●

about 2 months ago

Addex Provisional 2024 Third Quarter Results Showed Net Loss Compared to Second Quarter 2024

Nine-month Results Remain On Track for Net Profit Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 11, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its provisional third quarter net results decreased ...

More Addex Therapeutics Ltd - ADR News

Company Profile

Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. It develops novel, orally available, and small molecule allosteric modulators for neurological disorders. The company was founded by Vincent Mutel, Timothy Dyer, and Mark Epping-Jordan in 2002 and is headquartered in Geneva, Switzerland.

Head office	Switzerland
CEO	Tim Dyer
Employees	23
Founded	2002
Website	www.addextherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now